Acid Suppressing Drug Seizure Epidemiology Study

AstraZeneca

Status: Completed

Conditions: Seizure

Treatments: Drug: Risk of seizure

Study type: Observational

Funder types: Industry

Identifiers

NCT01744301

D9612N00017

Details and patient eligibility

About

The purpose of this study is

1. to estimate the incidence of seizure in the general population and stratified by epilepsy status
2. To estimate the relative risk of seizure associated with use of proton pump inhibitors and histamine 2 receptor antagonist and stratified by epilepsy status

Full description

A cohort study with a nested case control analysis on the association between acid-suppressing drugs and seizures using THIN database in the UK

Enrollment: 8,605 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Primary care physician for at least 2 years.
• Computerized prescription history of at least 1 year.
• Patients will have to be free of acid-suppressing drugs (PPI or H2RA) for at least one year.
• No diagnosis of cancer.
• No alcohol abuse or alcohol-related disease- No drug abuse.

Exclusion criteria

• Patients with at least 1 prescription of PPI or H2RA in the year prior to start date.
• Cancer before start date.
• Alcohol abuse or alcohol-related disease before start date.
• Drug abuse before start date.

Trial design

8,605 participants in 2 patient groups

All patients newly prescribed PPI

Description:

All patients newly prescribed PPI

Treatment:

Drug: Risk of seizure

All patients newly prescribed H2RA

Description:

All patients newly prescribed H2RA

Treatment:

Drug: Risk of seizure